Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02349802 · ClinicalTrials.gov registry record · Phase 1
Autoinjector Device Assessment Study
A Phase 1 study of Healthy Subjects, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 3,052
- Enrollment target
- 2
- Study locations
NCT02349802: Completed Phase 1 study of Healthy Subjects, sponsored by AstraZeneca.
NCT02349802 is a Phase 1 study of Healthy Subjects that has completed, run by AstraZeneca. The registered enrollment target is 3,052 participants, above the 84-participant average among 69 other Healthy Subjects trials with a reported enrollment target (3533% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02349802, a Phase 1 study of Healthy Subjects, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3,052 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.
Primary Outcome
The primary outcome measure is the number of device-related injection failures of the single-use, pre-filled auto-injector.
Conditions Studied
Interventions
- DRUG Auto-injector with exenatide suspension
- DRUG Syringe with exenatide suspension
Study Locations (2)
Arizona
- Research Site - Tempe
Nebraska
- Research Site - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,052 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT02349802 record still lists
NCT02349802 is an interventional study that assigns participants to a tested intervention. Its 3,052 participants enrollment target places it among the larger protocols in the corpus, above the 84-participant average among 69 other Healthy Subjects trials with a reported enrollment target (3533% higher).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which Auto-injector with exenatide suspension is the first listed.
NCT02349802 reports a single indexed study location in Arizona, Nebraska.
Frequently Asked Questions
What is clinical trial NCT02349802 about?
NCT02349802 is a clinical study titled "Autoinjector Device Assessment Study". Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.
What is the current status of trial NCT02349802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3,052 participants. The study started on 2013-02. Estimated completion is 2013-12.
What conditions does trial NCT02349802 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT02349802?
The interventions under investigation include: Auto-injector with exenatide suspension (DRUG), Syringe with exenatide suspension (DRUG).
Who is sponsoring clinical trial NCT02349802?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02349802 being conducted?
This trial has 2 study locations across Arizona, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02349802's enrollment target sits among peer trials
3,052 1st of 69 higher than 69 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia